Sitaxsentan, a selective endothelin-A receptor antagonist for the treatment of pulmonary arterial hypertension

Bibliography

• RICH S, DANTZKER DR, AYERS SM et al: Primary pulmonary hypertension: a national prospective study. Ann. Intern. Med. (1987) 107:216–233.
   PubMed Web of Science ®Google Scholar
• D'ALONZO GE, BARST RJ, AYRES SM et al.: Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann. Intern. Med. (1991) 115:343–349.1.
   Google Scholar
• GALIE N, RUBIN LJ: Pulmonary arterial hypertension: Epidemiology, pathobiology, assessment and therapy. I Am. Coll. Cardiol (2004) 43 (12) (Suppl. 5).
   Google Scholar
• RICH S, KAUFMANN E, LEVY PS: The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl. J. Med. (1992) 327(2):76–81.
   PubMed Web of Science ®Google Scholar
• YUNG D, WIDLITZ AC, ROSENZWEIG EB, KERSTEIN D, MAISLIN G, BARST RJ: Outcomes in children with idiopathic pulmonary arterial hypertension. Circulation (2004) 110(6):660–665.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RUBIN LJ, LONG WA et al: A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy in primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl. I Med. (1996) 334:296–301.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RUBIN LJ, McGOON MD, CALD WELL EJ, LONG WA, LEVY PS: Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann. Intern. Med. (1994) 121(6):409–415.
   PubMed Web of Science ®Google Scholar
• SIMONNEAU G, BARST RJ, GALIE N et al.: Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am. Respir. Grit. Care Med. (2002) 165(6):800–804.
   PubMed Web of Science ®Google Scholar
• CHANNICK RN, SIMONNEAU G, SITBON 0 et al: Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet (2001) 358(9288):1119–1123.
   PubMed Web of Science ®Google Scholar
• •The first of the two randomised clinical trials with bosentan in PAH that led to its approval for the treatment of PAH.
   Google Scholar
• RUBIN LJ, BADESCH DB, BARST RJ et al.: Bosentan therapy for pulmonary arterial hypertension. N Engl. I Med. (2002) 346(12):896–903.
   PubMed Web of Science ®Google Scholar
• •The second of the two randomised clinical trials with bosentan in PAH that led to its approval for the treatment of PAH.
   Google Scholar
• BARST RJ, IVY D, DINGEMANSE J et al: Single- and multiple-dose pharmacokinetics of bosentan in pediatric patients with pulmonary arterial hypertension. Clin. Pharmacol. Ther. (2003) 73:372–382.
   PubMed Web of Science ®Google Scholar
• YANAGISAWA M, KURIHARA H, KIMURA S et al: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (1988) 332(6163):411–415.
   PubMed Web of Science ®Google Scholar
• •Identification of ET-1.
   Google Scholar
• ARCHERS, RICH S: Primary pulmonary hypertension: a vascular biology and translational research 'work in progress'. Circulation (2000) 102(22):2781–2791.
   PubMed Web of Science ®Google Scholar
• LUSCHER TF, BARTON M: Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation (2000) 102(19):2434–2440.
   PubMed Web of Science ®Google Scholar
• GALIE N, MANES A, BRANZI A: The endothelin system in pulmonary arterial hypertension. Cardiovasc. Res. (2004) 61(2):227–237.
   PubMed Web of Science ®Google Scholar
• SPIEKER LE, NOLL G, RUSCHITZKA FT, LUSCHER TF: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?' Am. Coll. Cardiol (2001) 37(6):1493–505.
   PubMed Web of Science ®Google Scholar
• D'ORLEANS-JUSTE P, LABONTE J, BKAILY G, CHOUFANI S, PLANTE M, HONORE JC: Function of the endothelin B receptor in cardiovascular physiology and pathophysiology. Pharmacol Ther.(2002) 95(3):221–238.
   PubMed Web of Science ®Google Scholar
• JEFFERY TK, WANSTALL JC: Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. (2001) 91:1–20.
   PubMed Web of Science ®Google Scholar
• JOANNIDES R, HAEFELI WE, UNDER L et al: Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation (1995) 91:1314–1319.
   PubMed Web of Science ®Google Scholar
• KEDZIERSKI RM, YANAGISAWA M: Endothelin system: the double-edged sword in health and disease. Ann. Rev Pharmacol Toxicol (2001) 41:851–876.
   PubMed Web of Science ®Google Scholar
• BARST RJ, RICH S, WIDLITZ A, HORN EM, McLAUGHLIN V, McFARLIN J: Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest (2002) 121(6):1860–1868.
   PubMed Web of Science ®Google Scholar
• BARST RJ, LANGLEBEN D, FROST A, HORN EM, OUDIZ R, SHAPIRO S et al.: Sitaxsentan therapy for pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. (2004) 169(4):441–447.
   PubMed Web of Science ®Google Scholar
• RUBIN LJ, GALIE N, BADESCH D et al: Ambrisentan improves exercise capacity and clinical measures in pulmonary arterial hypertension (PAH). Am. I Respir Crit. Care Med. (2004) 169(7):A210.
   Google Scholar
• BOHM F, PERNOW J, LINDSTROM J, AHLBORG G: ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin-1 in the splanchnic and renal circulation of healthy men. Clia Sci. aono. (2003) 104(2):143–151.
   PubMed Web of Science ®Google Scholar
• VERHAAR MC, STRACHAN FE, NEWBY DE et al.: Endothelin-A receptor antagonist-mediated vasodilatation is attenuated by inhibition of nitric oxide synthesis and by endothelin-b receptor blockade. Circulation (1998) 97:752–756.
   PubMed Web of Science ®Google Scholar
• GODDARD J, JOHNSTON NR, HAND MF et al.: Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation (2004) 109(9):1186–1193.
   PubMed Web of Science ®Google Scholar
• LOVE MP, FERRO CJ, HAYNES WG et al.: Endothelin receptor antagonism in patients with chronic heart failure. Cardiovasc. Res. (2000) 47(1):166–172.
   PubMed Web of Science ®Google Scholar
• CHEN SJ, CHEN YF, OPGENORTH TJ et al: The orally active nonpeptide endothelin A-receptor antagonist A-127722 prevents and reverses hypoxia-induced pulmonary hypertension and pulmonary vascular remodeling in Sprague-Dawley rats. .1 Cardiovasc. Pharmacol (1997) 29(6):713–725.
   Google Scholar
• CHEN S-J, CHEN Y-F, MENG QC, DURAND J, DICARLO VS, OPARIL S: Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J. Appl. Physiol (1995) 79:2122–2131.
   PubMed Web of Science ®Google Scholar
• TILTON RG, MUNSCH CL, SHERWOOD SJ et al: Attenuation of pulmonary vascular hypertension and cardiac hypertrophy with sitaxsentan sodium, an orally active ET(A) receptor antagonist. Pulm. Pharmacol Ther. (2000) 13(2):87–97.
   PubMed Web of Science ®Google Scholar
• WU C, CHAN ME STAVROS F et al: Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J. Med. Chem. (1997) 40(10:1690–1697.
   PubMedGoogle Scholar
• •Identification of the selective ETA receptor antagonist sitaxsentan.
   Google Scholar
• ABRAHAM DJ, VANCHEESWARAN R, DASHWOOD MR et al.: Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol (1997) 151(3):831–841.
   PubMed Web of Science ®Google Scholar
• DAVIE N, HALEEN SJ, UPTON PD, POLAK JM, YACOUB MH, MORRELL NW, WHARTON J: ET(A) and ET(B) receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir Crit. Care Med. (2002) 165(3):398–405.
   PubMed Web of Science ®Google Scholar
• BAUER M, WILKENS H, LANGER F, SCHNEIDER SO, LAUSBERG H, SCHAFERS HJ: Selective upregulation of endothelin B receptor gene expression in severe pulmonary hypertension. Circulation. (2002) 105(9):1034–1036.
   PubMed Web of Science ®Google Scholar
• IVY D, MCMURTRY IF, YANAGISAWA M et al.: Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonary vasoconstriction. Am. .1 Physiol Lung Cell Mol Physiol (2001) 280(5)11040–L1048.
   Google Scholar
• MURAKOSHI N, MIYAUCHI T, KAKINUMA Y et al: Vascular endothelin-B receptor system in vivo plays a favorable inhibitory role in vascular remodeling after injury revealed by endothelin-B receptor-knockout mice. Circulation (2002) 106(15):1991–1998.
   PubMed Web of Science ®Google Scholar
• FORBES JM, HEWITSON TD, BECKER GJ, JONES CL: Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney In] (2001) 59:1333–1341.
   PubMed Web of Science ®Google Scholar
• WILLIAMSON DJ, WALLMAN LL, JONES R et al: Hemodynamic effects of Bosentan, an endothelin receptor antagonist, in patients with pulmonary hypertension. Circulation (2000) 102:411–418.
   PubMed Web of Science ®Google Scholar
• GODDARD J, JOHNSTON NR, HAND ME CUMMING AD, RABELINK TJ, RANKIN AJ, WEBB DJ: Enothelin-A Receptor Antagonism Reduces Blood Press. and increases renal blood flow in hypertensive patients with chronic renal failure. Circulation (2004) 109:1186–1193.
   Google Scholar
• GIVERTZ MM, COLUCCI WS, LEJEMTEL TH et al.: Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 101(25):2922–2927.
   PubMed Web of Science ®Google Scholar
• HALCOX JP, NOUR KR, ZALOS G, QUYYUMI AA: Coronary vasodilation and improvement in endothelial dysfunction with endothelin ET(A) receptor blockade. Circ. Res. (2001) 89(11):969–976.
   PubMed Web of Science ®Google Scholar
• CLOZEL M, BREU V, GRAY GA et al: Pharmacologic characterization of bosentan, a new potent orally active nonpeptide endothelin receptor antagonist. Pharmacol Exp. Ther. (1994) 270:228–235.
   PubMed Web of Science ®Google Scholar
• •Identifcation of the ETA/ETB receptor antagonist bosentan.
   Google Scholar
• VATTER H, ZIMMERMAN M, JUNG C, WEYRAUCH E, LANG J, SEIFERT V: Effect of the novel endothelin(A) receptor antagonist LU 208075 on contraction and relaxation of isolated rat basilar artery. OM Sci. (2002) 103\(Suppl. 48):4085–4135.
   Google Scholar
• BARST RJ, McGOON M, McLAUGHLIN V et al.: Beraprost therapy for pulmonary arterial hypertension. I Am. Coll. Cardiol (2003) 41(12):2119–2125.
   PubMed Web of Science ®Google Scholar
• FISHER LD. Carvedilol and the Food and Drug Administration (FDA) approval process: the FDA paradigm and reflections on hypothesis testing. Control. Clin. Trials (1999) 20(1):16–39.
   PubMedGoogle Scholar
• McLAUGHLIN VV, HILL N, TAPSON VF et al.: Sitaxsentan improves 6MW in patients with pulmonary arterial hypertension (PAH) related to connective-tissue diseases (CTD). Chest (2004).
   Google Scholar
• HORN E, LANGLEBEN D, FROST A et al: Chronic sitaxsentan in pulmonary arterial hypertension. Am. I Respir Grit. Care Med. (2004) 169(7):A210.
   Google Scholar
• LANGLEBEN D, HIRSCH AM, SHALIT E, LESENKO L, BARST RJ: Sustained 1491 Expert Op/n. Investig. Drugs (2004)13(11)
   Google Scholar
• •• Symptomatic, functional and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitazsentan, in patients with pulmonary arterial hypertension: a one year follow-up study. Chest (2004) 126:1377–1381.
   Google Scholar
• POOLE-WILSON PA, SWEDBERG K, CLELAND JG et al.: Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet (2003) 362(9377):7–13.
   PubMed Web of Science ®Google Scholar
• CLOUTHIER DE, HOSODA K, RICHARDSON JA et al.: Cranial and cardiac neural crest defects in endothelin-A receptor-deficient mice. Development (1998) 125:813–824.
   PubMed Web of Science ®Google Scholar
• DUPUIS J: Endothelin-receptor antagonists in pulmonary hypertension. Lancet (2001) 358(9288):1113–1114.
   PubMed Web of Science ®Google Scholar
• ••Review of the ET system in vascular tissue.
   Google Scholar